Cardiovascular safety signals with dipeptidyl peptidase-4 inhibitors: A disproportionality analysis among high-risk patients.
- Overview
- Research
- Identity
- Additional Document Info
- View All
Overview
publication date
- January 1, 2018
published in
has subject area
- Adamantane
- Administration, Oral
- Adverse Drug Reaction Reporting Systems
- Aged
- Bayes Theorem
- Databases, Factual
- Diabetes Mellitus, Type 2
- Dipeptides
- Dipeptidyl-Peptidase IV Inhibitors
- Female
- Heart Failure
- Humans
- Linagliptin
- Male
- Middle Aged
- Piperidines
- Practice Guidelines as Topic
- Sitagliptin Phosphate
- United States
- United States Food and Drug Administration
- Uracil